Bupivacaine extended release - Pacira BioSciences
Alternative Names: Bupivacaine extended-release - Pacira BioSciences; Bupivacaine extended-release liposome injection; Bupivacaine liposome extended-release injectable suspension; Bupivacaine liposome injectable suspension; DepoBupivacaine; Exparel; SKY-0402Latest Information Update: 13 May 2024
At a glance
- Originator SkyePharma Inc
- Developer Nuance Biotech; Pacira BioSciences; Pacira Pharmaceuticals
- Class Analgesics; Anilides; Anti-inflammatories; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Anaesthesia; Postoperative pain
- Phase III Dental pain
- No development reported Musculoskeletal pain; Pain
Most Recent Events
- 07 May 2024 Pacira BioSciences has patents protection for Bupivacaine extended release in US
- 30 Apr 2024 Foundation for Orthopaedic Research and Education and Pacira Pharmaceuticals initiates phase II/III trial for Post-operative pain in USA (NCT06350981)
- 07 Mar 2024 Phase-I clinical trials in Postoperative pain (In infants, In neonates, In children) in USA (Infiltration) (NCT06271265)